Is BioAtla, Inc. (BCAB) a Buy, Sell, or Hold?
NASDAQ : BCAB
BioAtla, Inc.
$3.33 USD
$0.01 (0.15%)
- Volume
- 39.46K
- Average Volume
- 48.92K
- Market Capitalization
- $4.2M
- P/E Ratio
- -0.08
- Dividend Yield
- 0.00%
- Price Target
- $250.00
- Year High
- $71.50
- Year Low
- $3.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.15
Company Overview
NASDAQ
Jay Short
Biotechnology
Healthcare
BCAB
41
US
USD
Liquidity Metrics
-0.16
0.15
0.15
0.09
0.00
Sales & Valuation
$2M
2.10
-0.13
-0.11
-24.76
Profitability
-$50.5
-$59.61M
-2530.85%
-2530.85%
166.67%
-590.91%
P/E Metrics
-0.08
0.00
0.00
Analyst Price Target & Rating
$250.00
$250.00
$250.00
2/5
9 Analysts
-98.67%
Financial Health Scores
-110.92
1/9
-$17.6M
$8.57M
$45.88M
-$48.1M
Key Metrics (TTM)
$8.33M
4.16
-0.17
0.15
166.67%
477.89%
-1013.76%
-886.80%
-470 days
Company Executives
| Name | Title |
|---|---|
| Jay Short | Co-Founder, Chief Executive Officer & Chairman |
| Sheri Lydick | Chief Commercial Officer |
| Gerhard Frey | Senior Vice President of Technology Development |
| Lisa Pelton | Accounting Manager |
| Susie Melody | Senior Vice President of Human Resources |
| Cathy Chang | Senior Vice President of Research & Development |
| Eric L. Sievers | Chief Medical Officer |
| Monica Sullivan | Senior Vice President of Intellectual Property & Contracts |
| Christian Vasquez | CFO, CAO, Controller & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About BioAtla, Inc. (NASDAQ:BCAB) Stock
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small ... cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 06:45:00
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Frequently Asked Questions
-
What is the current BioAtla, Inc. (BCAB) stock price?
-
BioAtla, Inc.(NASDAQ:BCAB) stock price is $3.33 in the last trading session. During the trading session, BCAB stock reached the peak price of $71.5 while $3.12 was the lowest point it dropped to. The percentage change in BCAB stock occurred in the recent session was 0.15% while the dollar amount for the price change in BCAB stock was $0.01.
-
BCAB's industry and sector of operation?
-
The NASDAQ listed BCAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCAB?
-
Jay Short | Co-Founder, Chief Executive Officer & Chairman
Sheri Lydick | Chief Commercial Officer
Gerhard Frey | Senior Vice President of Technology Development
Lisa Pelton | Accounting Manager
Susie Melody | Senior Vice President of Human Resources -
How many employees does BCAB have?
-
Number of BCAB employees currently stands at 41. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, US.
-
Link for BCAB official website?
-
Official Website of BCAB is: https://www.bioatla.com
-
How do I contact BCAB?
-
BCAB could be contacted at phone #858 558 0708 and can also be accessed through its website. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, US.
-
How many shares of BCAB are traded daily?
-
The average number of BCAB shares traded daily for last 3 months was 48.92K.
-
What is the market cap of BCAB currently?
-
The market value of BCAB currently stands at $4.2M with its latest stock price at $3.33